Transcend Capital Advisors LLC Has $233,000 Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Transcend Capital Advisors LLC lessened its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 10.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 19,692 shares of the company’s stock after selling 2,256 shares during the period. Transcend Capital Advisors LLC’s holdings in Roivant Sciences were worth $233,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares during the period. Covestor Ltd boosted its position in shares of Roivant Sciences by 9.1% during the third quarter. Covestor Ltd now owns 19,190 shares of the company’s stock valued at $222,000 after buying an additional 1,605 shares during the last quarter. US Bancorp DE boosted its position in shares of Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares during the last quarter. Quarry LP boosted its position in shares of Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after buying an additional 2,500 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new position in shares of Roivant Sciences during the third quarter valued at approximately $35,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ROIV. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $18.08.

Roivant Sciences Trading Down 0.4 %

ROIV stock opened at $10.68 on Monday. The stock’s fifty day simple moving average is $11.21 and its two-hundred day simple moving average is $11.60. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06. The stock has a market cap of $7.62 billion, a P/E ratio of -71.20 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CIO Mayukh Sukhatme sold 412,584 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total value of $4,971,637.20. Following the sale, the executive now directly owns 18,836,547 shares in the company, valued at $226,980,391.35. The trade was a 2.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Eric Venker sold 176,900 shares of the business’s stock in a transaction on Friday, December 27th. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00. Following the completion of the sale, the chief operating officer now owns 668,680 shares in the company, valued at approximately $7,903,797.60. The trade was a 20.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,288,170 shares of company stock worth $26,547,299 over the last ninety days. 7.90% of the stock is currently owned by company insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.